| ASO ID | Length | Sequence | Description |
|---|---|---|---|
| A04019H | 15 | +G* + T* + A*A*G*C*C*C*T*G*A*T* + G* + T* + T | Human specific ASO |
| A04040H | 16 | +G* + T* + T*T*G*T*G*T*G*A*G*A*G*C* + T* + T | Human specific ASO, used for in vitro experiments |
| A04042H | 17 | +T* + G* + C*C*A*G*A*G*T*G*C*C*T*G* + A* + T* + C | Human specific ASO |
| A04044H | 17 | +T* + T* + A*C*G*T*T*C*A*C*T*A*C*C* + T* + T* + C | Human specific ASO |
| A04045H | 17 | +C* + A* + C*T*T*A*C*G*T*T*C*A*C*T* + A* + C* + C | Human specific ASO |
| A04011MR | 16 | +A* + G* + T*A*A*T*C*C*A*C*C*C*A* + T* + A* + G | Mouse specific ASO, used for in vivo experiments, named: “CD39 ASO” in the text |
| Control oligo 1 | 18 | +C* + G* + T*T*T*A*G*G*C*T*A*T*G*T*A* + C* + T* + T | Control oligonucleotide, reference: PMID: 26072406, used for in vitro and in vivo experiments |
| Control oligo 2 | 17 | +T* + C* + T*A*T*C*G*T*G*A*T*G*T*T* + T* + C* + T | Control oligonucleotide, used for in vitro experiments |
+ indicates LNA-modified nucleotides and * indicates PTO linkages